Transplant & Leukemia Survival Rates | KK Women's and Children's Hospital

Transplant & Leukemia Survival Rates (2013 to 2022)

The Haematology/Oncology Service is a paediatric medical subspecialty that offers a comprehensive range of services for children and adolescents with cancers or complex blood disorders. Our clinical facilities include:

Paediatric Oncology Inpatient Ward and Children’s Day Therapy: These facilities provide a safe conducive environment for children with cancer to receive treatment and supportive care. In addition to patient rooms and cubicles, there is a Caregiver Corner, and a Family Resource Centre with a Playroom and a Teens Room supported by the Children's Cancer Foundation (CCF).
Blood and Marrow Transplantation and Cellular Therapy (BMTCT) unit: This consists of single-occupancy rooms with positive air pressure, double-doors, and HEPA air filters to maintain a safe protective environment for our most vulnerable patients. We have a Pheresis team to support cell harvesting for transplant and cell therapy, as well as therapeutic leukapheresis and plasma exchange procedures.

The KKH Children’s Blood and Cancer Centre is one of the largest paediatric and adolescent cancer centres in South-East Asia, treating 70% of childhood cancers diagnosed in Singapore. Each year, the centre sees around 100 new paediatric cancer cases of which 40% have leukaemia.

At KKH, the ten-year overall survival for non-high risk ALL is more than 95%. Collaborative studies between KKH, NUH and University of Malaya are on-going to refine the protocols by improving risk and treatment stratification. The goal is to maintain excellent outcomes with less intensive and therefore less toxic treatment for patients with lower risk disease, while introducing novel therapies (such as CAR T or improved transplant strategies) to improve outcomes for patients with high risk ALL.

Haematopoietic stem cell transplant is a treatment modality for the following diseases:

Malignant conditions such as leukaemia, lymphoma, high risk neuroblastoma
Non-malignant conditions such as bone marrow failure disorders, haemoglobinopathies, inborn errors of immunity, inborn errors of metabolism

For allogeneic haematopoietic cell transplant in the period of 2019-2023, the 30-day, 100-day and 1-year overall survival (OS) are 100%, 100% and 90.4% respectively, and the 30-day, 100-day and 1-year treatment-related mortality (TRM) are 0%, 0% and 3.3% respectively.

Our survival outcomes for the most common childhood cancer acute lymphoblastic leukamia is comparable to the best centres in the world. Our survival outcomes and transplant-related mortality rates for paediatric first allogenic hematopoietic cell transplant are also comparable to top centres with similar case volume.

References: